See more : G Medical Innovations Holdings Ltd (GMVDW) Income Statement Analysis – Financial Results
Complete financial analysis of Hubei Biocause Heilen Pharmaceutical Co., Ltd. (301211.SZ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Hubei Biocause Heilen Pharmaceutical Co., Ltd., a leading company in the Chemicals industry within the Basic Materials sector.
- Jayant Agro-Organics Limited (JAYAGROGN.NS) Income Statement Analysis – Financial Results
- LifeSafe Holdings plc (LIFS.L) Income Statement Analysis – Financial Results
- Litu Holdings Limited (1008.HK) Income Statement Analysis – Financial Results
- Shagrir Group Vehicle Services Ltd (SRRPF) Income Statement Analysis – Financial Results
- Morgan Stanley India Investment Fund, Inc. (IIF) Income Statement Analysis – Financial Results
Hubei Biocause Heilen Pharmaceutical Co., Ltd. (301211.SZ)
About Hubei Biocause Heilen Pharmaceutical Co., Ltd.
Hubei Biocause Heilen Pharmaceutical Co., Ltd. engages in the pharmaceutical, chemical, and new energy fuel businesses in China. It provides APIs and intermediates, and formulations; and dimethyl ether gas and chloropropionyl chloride chemical products. The company is based in Jingmen, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 663.03M | 514.91M | 540.62M | 592.92M | 660.02M | 517.14M | 366.41M |
| Cost of Revenue | 396.67M | 366.22M | 357.12M | 298.54M | 319.23M | 295.63M | 265.68M |
| Gross Profit | 266.35M | 148.69M | 183.50M | 294.38M | 340.79M | 221.52M | 100.73M |
| Gross Profit Ratio | 40.17% | 28.88% | 33.94% | 49.65% | 51.63% | 42.83% | 27.49% |
| Research & Development | 52.77M | 19.84M | 18.28M | 22.98M | 24.99M | 20.87M | 17.70M |
| General & Administrative | 13.35M | 8.87M | 9.56M | -13.05M | -33.99M | -47.21M | 8.65M |
| Selling & Marketing | 18.64M | 14.91M | 11.97M | 14.21M | 51.42M | 48.30M | 23.88M |
| SG&A | 31.99M | 23.77M | 21.53M | 1.16M | 17.43M | 1.09M | 32.54M |
| Other Expenses | -23.75M | -1.28M | -102.28K | 28.17M | 2.74M | 17.81M | -32.23K |
| Operating Expenses | 60.14M | 66.95M | 52.24M | 91.11M | 127.07M | 107.92M | 64.30M |
| Cost & Expenses | 457.69M | 433.17M | 409.36M | 389.64M | 446.29M | 403.55M | 329.98M |
| Interest Income | 47.84M | 61.02M | 2.40M | 13.82M | 1.69M | 1.04M | 278.22K |
| Interest Expense | 576.27K | 344.41K | 372.56K | 9.13M | 19.60M | 32.25M | 2.77M |
| Depreciation & Amortization | 21.76M | 21.76M | 19.37M | 18.19M | 21.76M | 16.05M | 15.77M |
| EBITDA | 225.15M | 169.77M | 158.92M | 219.33M | 236.83M | 129.61M | 45.46M |
| EBITDA Ratio | 33.96% | 32.59% | 29.53% | 37.05% | 39.39% | 32.71% | 13.34% |
| Operating Income | 205.33M | 148.73M | 139.29M | 198.96M | 218.10M | 107.45M | 26.96M |
| Operating Income Ratio | 30.97% | 28.88% | 25.76% | 33.56% | 33.04% | 20.78% | 7.36% |
| Total Other Income/Expenses | -2.52M | -1.28M | -102.28K | -328.30K | -1.10M | -826.42K | -32.23K |
| Income Before Tax | 202.82M | 147.44M | 139.18M | 198.63M | 217.00M | 106.62M | 26.92M |
| Income Before Tax Ratio | 30.59% | 28.63% | 25.75% | 33.50% | 32.88% | 20.62% | 7.35% |
| Income Tax Expense | 26.70M | 21.72M | 17.54M | 30.56M | 32.38M | 15.14M | 3.15M |
| Net Income | 176.12M | 125.79M | 121.65M | 168.07M | 100.29M | 47.74M | 10.27M |
| Net Income Ratio | 26.56% | 24.43% | 22.50% | 28.35% | 15.19% | 9.23% | 2.80% |
| EPS | 0.61 | 0.44 | 0.42 | 0.58 | 0.35 | 0.22 | 0.05 |
| EPS Diluted | 0.61 | 0.44 | 0.42 | 0.58 | 0.35 | 0.22 | 0.05 |
| Weighted Avg Shares Out | 288.72M | 288.00M | 288.00M | 288.00M | 288.00M | 212.16M | 205.35M |
| Weighted Avg Shares Out (Dil) | 288.72M | 288.00M | 288.00M | 288.00M | 288.00M | 212.16M | 205.35M |
Source: https://incomestatements.info
Category: Stock Reports